Posttranslational modifications of apolipoprotein A-II proteoforms in type 2 diabetes

Ida Azizkhanian; Olgica Trenchevska; Yara Bashawri; Jiaqi Hu; Juraj Koska; Peter D. Reaven; Randall W. Nelson; Dobrin Nedelkov; Hussein N. Yassine

doi:10.1016/j.jacl.2016.03.001

Posttranslational modifications of apolipoprotein A-II proteoforms in type 2 diabetes

Ida Azizkhanian, Olgica Trenchevska, Yara Bashawri, Jiaqi Hu, Juraj Koska, Peter D. Reaven, Randall W. Nelson, Dobrin Nedelkov, Hussein N. Yassine

Research output: Contribution to journal › Article

5 Scopus citations

Abstract

Background Apolipoprotein A-II (apoA-II) is the second most abundant protein in high-density lipoprotein particles. However, it exists in plasma in multiple forms. The effect of diabetes on apoA-II proteoforms is not known. Objective Our objective was to characterize plasma apoA-II proteoforms in participants with and without type 2 diabetes. Methods Using a novel mass spectrometric immunoassay, the relative abundance of apoA-II proteoforms was examined in plasma of 30 participants with type 2 diabetes and 25 participants without diabetes. Results Six apoA-II proteoforms (monomer, truncated TQ monomer, truncated Q monomer, dimer, truncated Q dimer, and truncated 2Qs dimer) and their oxidized proteoforms were identified. The ratios of oxidized monomer and all oxidized proteoforms to the native apoA-II were significantly greater in the diabetic group (P = .004 and P = .005, respectively) compared with the nondiabetic group. Conclusion The relative abundance of oxidized apoA-II is significantly increased in type 2 diabetes.

Original language	English (US)
Pages (from-to)	808-815
Number of pages	8
Journal	Journal of Clinical Lipidology
Volume	10
Issue number	4
DOIs	https://doi.org/10.1016/j.jacl.2016.03.001
State	Published - Jul 1 2016

Keywords

Apolipoprotein A-II
Diabetes
Mass spectrometry
Oxidations

ASJC Scopus subject areas

Internal Medicine
Endocrinology, Diabetes and Metabolism
Nutrition and Dietetics
Cardiology and Cardiovascular Medicine

Access to Document

10.1016/j.jacl.2016.03.001

Fingerprint Dive into the research topics of 'Posttranslational modifications of apolipoprotein A-II proteoforms in type 2 diabetes'. Together they form a unique fingerprint.

Cite this

Azizkhanian, I., Trenchevska, O., Bashawri, Y., Hu, J., Koska, J., Reaven, P. D., Nelson, R. W., Nedelkov, D., & Yassine, H. N. (2016). Posttranslational modifications of apolipoprotein A-II proteoforms in type 2 diabetes. Journal of Clinical Lipidology, 10(4), 808-815. https://doi.org/10.1016/j.jacl.2016.03.001

Posttranslational modifications of apolipoprotein A-II proteoforms in type 2 diabetes. / Azizkhanian, Ida; Trenchevska, Olgica; Bashawri, Yara; Hu, Jiaqi; Koska, Juraj; Reaven, Peter D.; Nelson, Randall W.; Nedelkov, Dobrin; Yassine, Hussein N.

In: Journal of Clinical Lipidology, Vol. 10, No. 4, 01.07.2016, p. 808-815.

Research output: Contribution to journal › Article

@article{793582f8b8ae42d7a06bbc158c5106db,

title = "Posttranslational modifications of apolipoprotein A-II proteoforms in type 2 diabetes",

abstract = "Background Apolipoprotein A-II (apoA-II) is the second most abundant protein in high-density lipoprotein particles. However, it exists in plasma in multiple forms. The effect of diabetes on apoA-II proteoforms is not known. Objective Our objective was to characterize plasma apoA-II proteoforms in participants with and without type 2 diabetes. Methods Using a novel mass spectrometric immunoassay, the relative abundance of apoA-II proteoforms was examined in plasma of 30 participants with type 2 diabetes and 25 participants without diabetes. Results Six apoA-II proteoforms (monomer, truncated TQ monomer, truncated Q monomer, dimer, truncated Q dimer, and truncated 2Qs dimer) and their oxidized proteoforms were identified. The ratios of oxidized monomer and all oxidized proteoforms to the native apoA-II were significantly greater in the diabetic group (P = .004 and P = .005, respectively) compared with the nondiabetic group. Conclusion The relative abundance of oxidized apoA-II is significantly increased in type 2 diabetes.",

keywords = "Apolipoprotein A-II, Diabetes, Mass spectrometry, Oxidations",

author = "Ida Azizkhanian and Olgica Trenchevska and Yara Bashawri and Jiaqi Hu and Juraj Koska and Reaven, {Peter D.} and Nelson, {Randall W.} and Dobrin Nedelkov and Yassine, {Hussein N.}",

year = "2016",

month = jul,

day = "1",

doi = "10.1016/j.jacl.2016.03.001",

language = "English (US)",

volume = "10",

pages = "808--815",

journal = "Journal of Clinical Lipidology",

issn = "1933-2874",

publisher = "Elsevier BV",

number = "4",

}

TY - JOUR

T1 - Posttranslational modifications of apolipoprotein A-II proteoforms in type 2 diabetes

AU - Azizkhanian, Ida

AU - Trenchevska, Olgica

AU - Bashawri, Yara

AU - Hu, Jiaqi

AU - Koska, Juraj

AU - Reaven, Peter D.

AU - Nelson, Randall W.

AU - Nedelkov, Dobrin

AU - Yassine, Hussein N.

PY - 2016/7/1

Y1 - 2016/7/1

N2 - Background Apolipoprotein A-II (apoA-II) is the second most abundant protein in high-density lipoprotein particles. However, it exists in plasma in multiple forms. The effect of diabetes on apoA-II proteoforms is not known. Objective Our objective was to characterize plasma apoA-II proteoforms in participants with and without type 2 diabetes. Methods Using a novel mass spectrometric immunoassay, the relative abundance of apoA-II proteoforms was examined in plasma of 30 participants with type 2 diabetes and 25 participants without diabetes. Results Six apoA-II proteoforms (monomer, truncated TQ monomer, truncated Q monomer, dimer, truncated Q dimer, and truncated 2Qs dimer) and their oxidized proteoforms were identified. The ratios of oxidized monomer and all oxidized proteoforms to the native apoA-II were significantly greater in the diabetic group (P = .004 and P = .005, respectively) compared with the nondiabetic group. Conclusion The relative abundance of oxidized apoA-II is significantly increased in type 2 diabetes.

AB - Background Apolipoprotein A-II (apoA-II) is the second most abundant protein in high-density lipoprotein particles. However, it exists in plasma in multiple forms. The effect of diabetes on apoA-II proteoforms is not known. Objective Our objective was to characterize plasma apoA-II proteoforms in participants with and without type 2 diabetes. Methods Using a novel mass spectrometric immunoassay, the relative abundance of apoA-II proteoforms was examined in plasma of 30 participants with type 2 diabetes and 25 participants without diabetes. Results Six apoA-II proteoforms (monomer, truncated TQ monomer, truncated Q monomer, dimer, truncated Q dimer, and truncated 2Qs dimer) and their oxidized proteoforms were identified. The ratios of oxidized monomer and all oxidized proteoforms to the native apoA-II were significantly greater in the diabetic group (P = .004 and P = .005, respectively) compared with the nondiabetic group. Conclusion The relative abundance of oxidized apoA-II is significantly increased in type 2 diabetes.

KW - Apolipoprotein A-II

KW - Diabetes

KW - Mass spectrometry

KW - Oxidations

UR - http://www.scopus.com/inward/record.url?scp=84963969074&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84963969074&partnerID=8YFLogxK

U2 - 10.1016/j.jacl.2016.03.001

DO - 10.1016/j.jacl.2016.03.001

M3 - Article

C2 - 27578111

AN - SCOPUS:84963969074

VL - 10

SP - 808

EP - 815

JO - Journal of Clinical Lipidology

JF - Journal of Clinical Lipidology

SN - 1933-2874

IS - 4

ER -